In this episode of The Promise of Personalized Medicine, Perry sits down with Dr. Ryan Nelson, to explore the evolving and sometimes misunderstood world of personalized medicine. With years of hands-on experience, Dr. Nelson offers a refreshingly nuanced definition—one that goes beyond genetics to include biomarkers, digital tools, and system-wide collaboration for predictive, preventative, and precisely tailored care.We dive deep into:the challenges and slow adoption of pharmacogenetics in the U.S.the ethical and regulatory friction surrounding genetic testingwhy "genetic exceptionalism" may actually hinder progressthe FDA’s shifting role to real-world cost savings dataRyan also shares a behind-the-scenes look at MetaCensus, a new distributed platform designed to foster consensus among stakeholders through open-access, federated data—creating space for payers, providers, pharma, and regulators to weigh evidence transparently.—-------Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at [email protected] 🔗 Connect on LinkedIn: linkedin.com/company/accessdx

Ver todos los episodios